Artiva Biotherapeutics, Inc.
4.3900-0.34 (-7.19%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · ARTV · USD
Key Stats
Market Cap
107.23MP/E (TTM)
-Basic EPS (TTM)
-6.15Dividend Yield
0%Recent Filings
8-K
Artiva's Q2 loss widens on trials
Artiva Biotherapeutics reported Q2 2025 net loss of $21.3 million, up from $17.8 million last year, driven by $17.9 million in R&D expenses versus $12.3 million, while holding $142.4 million in cash to fund operations into Q2 2027. The company dosed its first patient in a global Phase 2a basket trial of AlloNK plus rituximab for refractory rheumatoid arthritis, Sjögren’s, myositis, and scleroderma, with over a dozen patients treated across multiple autoimmune trials. Initial safety and translational data arrive by year-end 2025. Cash burn accelerates amid trial expansion.
10-Q
Q2 FY2025 results
Artiva Biotherapeutics posted a $21.3M net loss for Q2 FY2025 ended June 30, 2025, up 19% y/y from $17.8M, driven by $17.9M R&D expenses (up 45% y/y, mainly AlloNK clinical trials) and $4.9M G&A (up 28% y/y, from headcount). Operating loss widened to $22.8M from $16.2M y/y, with net loss matching operating due to $1.6M interest income offsetting minor other items. Cash and equivalents fell to $28.5M from $40.2M at year-end, with $142.4M total liquidity supporting operations into Q2 2027; free cash flow not disclosed in the 10-Q. No revenue or debt noted. NK cell therapies face stiff competition from CAR-T rivals in autoimmune indications.
8-K
Stockholders approve equity plan boost
Artiva Biotherapeutics stockholders approved an amendment to the 2024 Equity Incentive Plan at the June 24, 2025 annual meeting, boosting the share reserve by 1,214,580 shares to fuel talent retention amid biotech competition. Daniel Baker, Ph.D., secured election as Class I director with overwhelming support, while KPMG's auditor role passed unanimously. This bolsters equity incentives. Yet dilution looms for shareholders.
10-Q
Q1 FY2025 results
Artiva Biotherapeutics posted a Q1 net loss of $20.3 million, up from $14.0 million a year earlier, as research and development expenses climbed 53% year-over-year to $17.1 million, driven by $7.5 million in AB-101 (AlloNK) costs for advancing clinical trials in autoimmune diseases like SLE and lupus nephritis. While revenue from development support dried up to zero from $0.3 million, interest income nearly tripled to $1.9 million on a larger investment portfolio. Cash and equivalents dipped to $30.4 million from $40.2 million quarter-over-quarter, with total liquidity at $166.0 million, supporting operations into Q2 2027; free cash flow was not disclosed in the 10-Q. No debt burdens or M&A events surfaced. Yet competition from established cell therapies looms large.
8-K
AlloNK trial launches in autoimmunity
Artiva Biotherapeutics kicked off its global Phase 2a basket trial for AlloNK plus rituximab in refractory rheumatoid arthritis, Sjögren’s disease, myositis, and scleroderma after FDA IND clearance, marking the first U.S. company-sponsored allogeneic cell therapy effort in RA and Sjögren’s. Cash reserves hit $166.0 million as of March 31, 2025, funding operations into Q2 2027, while R&D expenses climbed to $17.1 million from $11.2 million year-over-year amid net loss of $20.3 million. Initial safety data arrives by year-end 2025. Trial success hinges on community-site tolerability.
ADPT
Adaptive Biotechnologies Corpor
16.80-0.10
ALLO
Allogene Therapeutics, Inc.
1.22-0.04
ARMP
Armata Pharmaceuticals, Inc.
5.46+0.47
ARQT
Arcutis Biotherapeutics, Inc.
25.29+0.34
ATRA
Atara Biotherapeutics, Inc.
14.06-1.15
AURX
Nuo Therapeutics, Inc.
2.29+0.00
IBRX
ImmunityBio, Inc.
2.42-0.16
KYTX
Kyverna Therapeutics, Inc.
7.17-0.44
NKTX
Nkarta, Inc.
2.09-0.22
RVPH
Reviva Pharmaceuticals Holdings
0.59+0.01